Esophageal and Gastric Cancer Pearl: a nationwide clinical biobanking project in the Netherlands
Leonie Haverkamp(University Medical Center Utrecht), Jelle P. Ruurda(University Medical Center Utrecht), Mark I. van Berge Henegouwen(University of Namur), Jan H.M.B. Stoot, Bas P. L. Wijnhoven(Erasmus MC Cancer Institute), Hanneke W.M. van Laarhoven(Dutch Cancer Society), Tanya M. Bisseling(Radboud University Nijmegen), H. W. Verspaget(Parnassia Groep), Richard van Hillegersberg(University Medical Center Utrecht), Johannes J. Bonenkamp, Kevin Parry(University Medical Center Utrecht), Peter D. Siersema(University Medical Center Utrecht), Wobbe O. de Steur(Leiden University Medical Center), John Th. M. Plukker(University Medical Center Groningen), Meindert N. Sosef(Zuyderland Medisch Centrum), Geerard L. Beets(The Netherlands Cancer Institute), Boudewijn van Etten(University Medical Center Groningen), Donald L. van der Peet(Amsterdam UMC Location Vrije Universiteit Amsterdam), H.H. Hartgrink(Leiden University Medical Center), J. J. van Lanschot(Erasmus MC)
Cited by 10
Related Papers
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
|New England Journal of Medicine|2012|5.5k
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
|The Lancet Oncology|2015|2.6k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
|Journal of Clinical Oncology|2021|795
Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial
|The Lancet. Gastroenterology & hepatology|2019|597